206 related articles for article (PubMed ID: 26208356)
1. A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen.
Vijayan A; García-Arriaza J; Raman SC; Conesa JJ; Chichón FJ; Santiago C; Sorzano CÓ; Carrascosa JL; Esteban M
PLoS One; 2015; 10(7):e0133595. PubMed ID: 26208356
[TBL] [Abstract][Full Text] [Related]
2. Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.
Guerra S; González JM; Climent N; Reyburn H; López-Fernández LA; Nájera JL; Gómez CE; García F; Gatell JM; Gallart T; Esteban M
J Virol; 2010 Aug; 84(16):8141-52. PubMed ID: 20534857
[TBL] [Abstract][Full Text] [Related]
3. Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans.
Zhao LP; Fiore-Gartland A; Carpp LN; Cohen KW; Rouphael N; Fleurs L; Dintwe O; Zhao M; Moodie Z; Fong Y; Garrett N; Huang Y; Innes C; Janes HE; Lazarus E; Michael NL; Nitayaphan S; Pitisuttithum P; Rerks-Ngarm S; Robb ML; De Rosa SC; Corey L; Gray GE; Seaton KE; Yates NL; McElrath MJ; Frahm N; Tomaras GD; Gilbert PB
PLoS One; 2020; 15(1):e0226803. PubMed ID: 31999736
[TBL] [Abstract][Full Text] [Related]
4. Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa.
Zambonelli C; Dey AK; Hilt S; Stephenson S; Go EP; Clark DF; Wininger M; Labranche C; Montefiori D; Liao HX; Swanstrom RI; Desaire H; Haynes BF; Carfi A; Barnett SW
PLoS One; 2016; 11(7):e0157391. PubMed ID: 27442017
[TBL] [Abstract][Full Text] [Related]
5. Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial.
Campion SL; Brenna E; Thomson E; Fischer W; Ladell K; McLaren JE; Price DA; Frahm N; McElrath JM; Cohen KW; Maenza JR; Walsh SR; Baden LR; Haynes BF; Korber B; Borrow P; McMichael AJ
J Clin Invest; 2021 Dec; 131(23):. PubMed ID: 34850742
[TBL] [Abstract][Full Text] [Related]
6. Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.
Churchyard G; Mlisana K; Karuna S; Williamson AL; Williamson C; Morris L; Tomaras GD; De Rosa SC; Gilbert PB; Gu N; Yu C; Mkhize NN; Hermanus T; Allen M; Pensiero M; Barnett SW; Gray G; Bekker LG; Montefiori DC; Kublin J; Corey L
PLoS One; 2016; 11(9):e0161753. PubMed ID: 27583368
[TBL] [Abstract][Full Text] [Related]
7. Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature.
Cheng C; Duan H; Xu K; Chuang GY; Corrigan AR; Geng H; O'Dell S; Ou L; Chambers M; Changela A; Chen X; Foulds KE; Sarfo EK; Jafari AJ; Hill KR; Kong R; Liu K; Todd JP; Tsybovsky Y; Verardi R; Wang S; Wang Y; Wu W; Zhou T; ; Arnold FJ; Doria-Rose NA; Koup RA; McDermott AB; Scorpio DG; Worobey M; Shapiro L; Mascola JR; Kwong PD
Cell Rep; 2020 Aug; 32(5):107981. PubMed ID: 32755575
[TBL] [Abstract][Full Text] [Related]
8. Heterologous prime-boost vaccination with DNA and MVA vaccines, expressing HIV-1 subtype C mosaic Gag virus-like particles, is highly immunogenic in mice.
Chapman R; Jongwe TI; Douglass N; Chege G; Williamson AL
PLoS One; 2017; 12(3):e0173352. PubMed ID: 28278263
[TBL] [Abstract][Full Text] [Related]
9. Type I Interferon Promotes Humoral Immunity in Viral Vector Vaccination.
Zhong C; Liu F; Hajnik RJ; Yao L; Chen K; Wang M; Liang Y; Sun J; Soong L; Hou W; Hu H
J Virol; 2021 Oct; 95(22):e0092521. PubMed ID: 34495698
[TBL] [Abstract][Full Text] [Related]
10. Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes.
Aboud S; Nilsson C; Karlén K; Marovich M; Wahren B; Sandström E; Gaines H; Biberfeld G; Godoy-Ramirez K
Clin Vaccine Immunol; 2010 Jul; 17(7):1124-31. PubMed ID: 20463104
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.
García-Arriaza J; Garaigorta U; Pérez P; Lázaro-Frías A; Zamora C; Gastaminza P; Del Fresno C; Casasnovas JM; Sorzano CÓS; Sancho D; Esteban M
J Virol; 2021 Mar; 95(7):. PubMed ID: 33414159
[TBL] [Abstract][Full Text] [Related]
12. Contribution of TLR4 and MyD88 for adjuvant monophosphoryl lipid A (MPLA) activity in a DNA prime-protein boost HIV-1 vaccine.
Pouliot K; Buglione-Corbett R; Marty-Roix R; Montminy-Paquette S; West K; Wang S; Lu S; Lien E
Vaccine; 2014 Sep; 32(39):5049-56. PubMed ID: 25045815
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge.
Jones AT; Shen X; Walter KL; LaBranche CC; Wyatt LS; Tomaras GD; Montefiori DC; Moss B; Barouch DH; Clements JD; Kozlowski PA; Varadarajan R; Amara RR
Nat Commun; 2019 Feb; 10(1):798. PubMed ID: 30778066
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques.
Thomas MA; Tuero I; Demberg T; Vargas-Inchaustegui DA; Musich T; Xiao P; Venzon D; LaBranche C; Montefiori DC; DiPasquale J; Reed SG; DeVico A; Fouts T; Lewis GK; Gallo RC; Robert-Guroff M
Virology; 2014 Dec; 471-473():81-92. PubMed ID: 25461534
[TBL] [Abstract][Full Text] [Related]
15. Vaccines expressing the innate immune modulator EAT-2 elicit potent effector memory T lymphocyte responses despite pre-existing vaccine immunity.
Aldhamen YA; Seregin SS; Schuldt NJ; Rastall DP; Liu CJ; Godbehere S; Amalfitano A
J Immunol; 2012 Aug; 189(3):1349-59. PubMed ID: 22745373
[TBL] [Abstract][Full Text] [Related]
16. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers.
Wang S; Kennedy JS; West K; Montefiori DC; Coley S; Lawrence J; Shen S; Green S; Rothman AL; Ennis FA; Arthos J; Pal R; Markham P; Lu S
Vaccine; 2008 Feb; 26(8):1098-110. PubMed ID: 18243434
[TBL] [Abstract][Full Text] [Related]
17. Induction of immunity to human immunodeficiency virus type-1 by vaccination.
McElrath MJ; Haynes BF
Immunity; 2010 Oct; 33(4):542-54. PubMed ID: 21029964
[TBL] [Abstract][Full Text] [Related]
18. Persistent antibody responses but declining cytotoxic T-lymphocyte responses to multiple human immunodeficiency virus type 1 antigens in a long-term nonprogressing individual with a defective p17 proviral sequence and no detectable viral RNA expression.
Binley JM; Jin X; Huang Y; Zhang L; Cao Y; Ho DD; Moore JP
J Virol; 1998 Apr; 72(4):3472-4. PubMed ID: 9525685
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 envelope resistance to proteasomal cleavage: implications for vaccine induced immune responses.
Steers NJ; Ratto-Kim S; de Souza MS; Currier JR; Kim JH; Michael NL; Alving CR; Rao M
PLoS One; 2012; 7(8):e42579. PubMed ID: 22880042
[TBL] [Abstract][Full Text] [Related]
20. A versatile vector for the production of pseudotyped viruses expressing gp120 antigens from different clades of primary HIV-1 isolates.
Wang Z; Zhang M; Wang Y; Jiao Y; Zhang L; Li L; Huang Z; Wu H; Li J; Lu S; Wang S
J Virol Methods; 2011 Jan; 171(1):183-9. PubMed ID: 21034776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
